drugset / Trial / NCT00132119

Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling

NCT00132119

Phase 2/3 Completed 233 enrolled Somaxon Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine if nalmefene is safe and effective in the treatment of pathological gambling.

Timeline

Start
2005-08
Primary completion
2006-08
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Nalmefene Small molecule 20 mg Oral
Subject Nalmefene Small molecule 40 mg Oral

Indications